Valuation: Agios Pharmaceuticals, Inc.

Market Cap 1.93B 1.67B 1.56B 1.43B 2.69B 183B 2.73B 18.26B 7.17B 91.9B 7.23B 7.08B 304B P/E 2026 *
-5.68x
P/E 2027 * -8.36x
Enterprise Value 1.67B 1.44B 1.35B 1.24B 2.33B 159B 2.36B 15.82B 6.21B 79.61B 6.27B 6.13B 263B EV / Sales 2026 *
9.15x
EV / Sales 2027 * 5.26x
Free-Float
75.42%
Yield 2026 *
-
Yield 2027 * -
1 day+1.00%
1 week+7.50%
Current month+7.50%
1 month-24.53%
3 months+16.12%
6 months+21.64%
Current year+18.55%
1 week 29.32
Extreme 29.32
32.61
1 month 29.15
Extreme 29.15
42.93
Current year 24.29
Extreme 24.29
44.09
1 year 22.24
Extreme 22.24
46
3 years 19.8
Extreme 19.795
62.58
5 years 16.75
Extreme 16.75
62.58
10 years 16.75
Extreme 16.75
99.82
Manager TitleAgeSince
Chief Executive Officer 57 08/08/2022
Director of Finance/CFO 51 26/09/2022
Chief Tech/Sci/R&D Officer 47 01/09/2021
Director TitleAgeSince
Director/Board Member 66 09/12/2014
Director/Board Member 73 23/06/2015
Director/Board Member 73 27/05/2017
Date Insider Type Main position Quantity % Market Cap.
04/08/26 Sell

Chief Technology Officer

-30,000 0.0504%
08/07/26 Free

Director

2,894 0.0049%
01/07/26 Fiscal year

Chief Technology Officer

20,757 0.0349%
Change 5-day change 1-year change 3-year change Capi.($)
+1.00%+7.50%-9.76%+24.12% 1.93B
+8.49%+20.55%+70.77%+110.32% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+10.83%+18.38%+56.20%+6.03% 23.99B
+2.72%+3.41%-16.11%-7.96% 23.53B
+6.50%+7.56%+44.65%-21.73% 18.45B
+6.20%+11.51%+33.87%+693.38% 16.44B
-3.88%+16.98%+199.30%+359.77% 15.83B
+3.58%+1.96%+43.35%+163.76% 13.4B
Average +3.56%+11.26%+47.62%+189.27% 26.55B
Weighted average by Cap. +4.33%+13.05%+50.25%+167.43%

Financials

2026 *2027 *
Net sales 182M 158M 147M 135M 254M 17.37B 258M 1.73B 679M 8.71B 685M 670M 28.78B 340M 294M 275M 252M 474M 32.34B 481M 3.22B 1.26B 16.21B 1.28B 1.25B 53.59B
Net income -338M -292M -273M -250M -471M -32.17B -479M -3.2B -1.26B -16.12B -1.27B -1.24B -53.31B -240M -208M -194M -178M -335M -22.85B -340M -2.28B -893M -11.46B -902M -882M -37.87B
Net Debt -258M -223M -208M -191M -359M -24.52B -365M -2.44B -958M -12.29B -967M -946M -40.63B -137M -119M -111M -102M -191M -13.08B -195M -1.3B -511M -6.55B -516M -505M -21.67B
Logo Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Employees
540
Date Price Change Volume
07/08/26 $32.27 +1.00% 1,399,666
06/08/26 $31.95 +0.73% 1,188,198
05/08/26 $31.72 +0.38% 915,635
04/08/26 $31.60 +3.47% 1,072,529
03/08/26 $30.54 +1.73% 1,189,503
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
32.27USD
Average target price
45.75USD
Spread / Average Target
+41.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGIO Stock